Rochaix Lise, Xerri Bertrand
Economic and Public Health Specialized Committee, Haute Autorité de Santé.
Issue Brief (Commonw Fund). 2009 Jul;58:1-9.
The French National Authority for Health (Haute Autorité de Santé, or HAS) was established to assist France's public institutions in optimizing the basket of reimbursable goods and services and to help health care professionals continuously improve their clinical practice by defining best-care standards and identifying relevant tools and methods. HAS carries out single technology assessment (STA) and multiple technology assessment (MTA), assessing both the intrinsic benefit of the new technology and its effectiveness compared with that of existing technologies. A new treatment may not be covered unless it provides either improved benefit or lower cost, and STA is mandatory before a new drug, device, or medical procedure can be added to the benefit list for sickness funds. While HAS recommendations are advisory, the decision-making bodies (the Ministry of Health or the union of sickness funds) accept its findings in most cases.
法国国家卫生管理局（法语：Haute Autorité de Santé，简称HAS）的设立旨在协助法国公共机构优化可报销商品和服务清单，并通过界定最佳医疗标准以及识别相关工具和方法，帮助医疗保健专业人员持续改进其临床实践。HAS开展单一技术评估（STA）和多重技术评估（MTA），既评估新技术的内在益处，也评估其与现有技术相比的有效性。除非新疗法能带来更高益处或更低成本，否则不予报销，并且在新药、新设备或新医疗程序被纳入疾病基金福利清单之前，STA是强制性要求。虽然HAS的建议仅供参考，但决策机构（卫生部或疾病基金联盟）在大多数情况下会接受其评估结果。
